SynthesisCNS drugs2017
A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder.
Synthesis in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- A systematic review of the role of clozapine for severe borderline personality disorder.Psychopharmacology · 2023Pooled it
- Evaluation of international guidance for the community treatment of 'personality disorders': A systematic review.PloS one · 2023Pooled it
- Pharmacological interventions for people with borderline personality disorder.The Cochrane database of systematic reviews · 2022Pooled it
- Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis.CNS drugs · 2021Pooled it
- Assessment of neurotransmitter-related structural brain changes in borderline personality disorder: an MRI study.Scientific reports · 2026Article
- Evaluation of Adherence to Pharmacological Treatment in a Large Sample of Patients with Personality Disorder.Clinical neuropsychiatry · 2025Article
- An In Vivo Examination of the Relationship Between Metabotropic Glutamate 5 Receptor and Suicide Attempts in People With Borderline Personality Disorder.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Article
- Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis.Psychiatry research communications · 2024Review
- Association between quetiapine use and self-harm outcomes among people with recorded personality disorder in UK primary care: A self-controlled case series analysis.Journal of psychopharmacology (Oxford, England) · 2022Article
- The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.Current treatment options in psychiatry · 2022Article
- The Emerging Circadian Phenotype of Borderline Personality Disorder: Mechanisms, Opportunities and Future Directions.Current psychiatry reports · 2021Review
- Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice.BMC psychiatry · 2019Article
- A Life Span Perspective on Borderline Personality Disorder.Current psychiatry reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedicines are routinely prescribed to treat borderline personality disorder (BPD) despite a relative lack of high-quality evidence and in breach of some treatment guidelines. An earlier Cochrane review of pharmacotherapy in BPD underlined the lack of evidence, encouraged the replication of earlier studies, but also emphasised the pressing need for more randomised placebo-controlled trials, and for those studies to employ broadened inclusion criteria.
methodThe authors searched bibliographic databases, reference lists of articles and trials registers. Records were screened to identify those that met the inclusion criteria. Full-text articles were screened and assessed for eligibility. On-going trials of pharmacotherapy in BPD were also identified.
resultsFifteen new studies of pharmacotherapy for BPD were identified since the earlier review. Eight of those examined second generation antipsychotics, two investigated mood stabilisers, three investigated antidepressants and two studied the effectiveness of opioid antagonists. Results for the effectiveness of antipsychotics appeared to be mixed. There has been little recent evidence to support the use of mood stabilisers. There is a lack of new placebo-controlled, randomised controlled trials investigating antidepressants and limited new evidence to support the use of opioid antagonists.
conclusionsThe review revealed that there remains a dearth of high-quality research evidence to help patients, carers and clinicians make sound and safe evidence-based decisions about medicines to treat BPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.